Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PU3T | ISIN: US81642T2096 | Ticker-Symbol: RXK3
Tradegate
06.06.25 | 16:06
1,430 Euro
+0,14 % +0,002
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SELLAS LIFE SCIENCES GROUP INC Chart 1 Jahr
5-Tage-Chart
SELLAS LIFE SCIENCES GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4321,45217:30
1,4321,45217:30

Aktuelle News zur SELLAS LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSELLAS adds oncology experts to advisory board2
DoSELLAS erweitert wissenschaftlichen Beirat mit Onkologie-Experten-
SELLAS LIFE SCIENCES Aktie jetzt für 0€ handeln
DoSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts2
MoSELLAS reports potential colorectal cancer therapy progress5
MoSELLAS Life Sciences Group, Inc.: SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting196- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer - - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in...
► Artikel lesen
20.05.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase15
15.05.SELLAS advances pediatric AML treatment with Phase 2 trial3
15.05.SELLAS treibt Behandlung von pädiatrischer AML mit Phase-2-Studie voran6
15.05.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML577NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of...
► Artikel lesen
13.05.SELLAS Life Sciences GAAP EPS of -$0.07 beats by $0.043
13.05.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update128- Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC...
► Artikel lesen
13.05.SELLAS Life Sciences Group, Inc. - 8-K, Current Report1
13.05.SELLAS Life Sciences Group, Inc. - 10-Q, Quarterly Report1
28.04.SELLAS berichtet über vielversprechende AML-Behandlung in präklinischer Studie14
28.04.SELLAS reports promising AML treatment in preclinical study1
23.04.SELLAS Life Sciences Group, Inc.: SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting5
08.04.SELLAS succeeds in mid-stage study for myeloid leukemia treatment4
08.04.SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML251- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing...
► Artikel lesen
20.03.SELLAS Life Sciences GAAP EPS of -$0.50 beats by $0.043
20.03.SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update364- Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events...
► Artikel lesen
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1